Efficacy of JAK Inhibitors versus DMARDs in the Treatment of Polymyalgia Rheumatica in China
Juanfang Gu,Mingfeng Yang,Bin Zhang,Hongzhi Wang
DOI: https://doi.org/10.2147/IJGM.S414267
IF: 2.145
2023-07-13
International Journal of General Medicine
Abstract:Juanfang Gu, 1, 2 Mingfeng Yang, 1, 2 Bin Zhang, 1, 2 Hongzhi Wang 1, 2 1 Department of Rheumatology and Immunology, The Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, Zhejiang, 314300, People's Republic of China; 2 Jiaxing Key Laboratory of Osteoporosis and Bone Metabolism, Jiaxing, Zhejiang, 314300, People's Republic of China Correspondence: Hongzhi Wang; Bin Zhang, Email ; Objective: This retrospective analysis was to assess the role of Janus kinases (JAK) inhibitors compared with conventional disease modifying anti-rheumatic drugs (DMRADs) in the treatment of polymyalgia rheumatica (PMR) with glucocorticoids (GCs) reduction. Methods: Clinical information was collected from PMR patients in the JAK inhibitor group and the DMARDs group from January 2020 to August 2021 at Jiaxing first Hospital. Serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), hemoglobin (Hb), albumin and dose of GCs before and after treatment were compared between two groups. Results: Thirty female patients with PMR were included into this study. The dose of GCs in the JAK inhibitor group was significantly lower than in the DMARDs group at baseline and at 3 and 6 months after treatment. There were no significant differences in various laboratory parameters (including CRP, ESR, Hb and albumin) between two groups (P > 0.05) except that Hb in the DMARDs group was significantly higher than in the JAK inhibitor group at 3 and 6 months after treatment (P< 0.05). One patient in the JAK inhibitor group developed herpes zoster, and received tofacitinib treatment after herpes zoster was relieved. Conclusion: Our study indicates that JAK inhibitors in the treatment of PMR are as effective as DMRADs and are also helpful for the reduction of GCs dose. Keywords: JAK inhibitors, polymyalgia rheumatica, glucocorticoids, disease modifying anti-rheumatic drug Polymyalgia rheumatica (PMR) is a chronic inflammatory disease of unknown etiology 1, exclusively affecting people over 50 years of age. PMR affects about 2.4% of women and 1.7% of men, its incidence ranks only second to rheumatoid arthritis and it has been one of the most common inflammatory rheumatic diseases in the older adults. 1 PMR is characterized by scapular and pelvic girdle pain, morning stiffness, and elevated acute phase reactants, and is sensitive to glucocorticoids (GCs) therapy. 2 Currently, GCs are still considered the cornerstone in treatment for PMR. 3 A systematic review and meta-analysis showed that the proportion of PMR patients receiving GCs for 1, 2 and 5 years was 77% (95% CI 71–83%), 51% (95% CI 41–61%) and 25% (95% CI 15–36%), respectively. 4 In addition, an observational study revealed that it was difficult to completely discontinue GCs therapy in women with PMR. 5 However, the long-term use of GCs raises great concern, especially in older patients, because it is closely associated with recognized adverse effects. Therefore, increasing guidelines have recommended the disease-modifying antirheumatic drugs (DMARDs) in combination with GCs for the disease control and synergistic GCs reduction. Methotrexate (MTX) is recommended more frequently in available guidelines, but tumor necrosis factor (TNF) inhibitors are not recommended for PMR, and there are no recommendations for other biologics. 6,7 Several studies have shown that tocilizumab, an anti-IL-6 receptor monoclonal antibody, is effective and safe in the treatment of PMR. 8–11 To date, the use of sarilumab has been approved in the US. However, the therapeutic efficacy of Janus kinase (JAK) inhibitors, which inhibit the IL-6 signaling pathway, in PMR is unclear. In the present study, PMR patients treated with JAK inhibitors at our institution were retrospectively analyzed and patients receiving conventional DMARDs treatment during the same period served as controls. This study was to evaluate the role of JAK inhibitors in the treatment of PMR with synergistic GCs reduction, which may provide an alternative treatment for PMR. The clinical information was collected from 18 PMR patients who were treated with JAK inhibitors in the Department of Rheumatology, the first Hospital of Jiaxing City from January 2020 to August 2021. Data from three patients were not included in the final analysis, including two patients with missing data on relevant laboratory tests and one 91-year-old patient with recurrent infection. In addition, clinical information was also collected from 24 PMR patients treated with conventional DMARDs who were matched by age and gender during the same period. Nine PMR patients treated with tripter -Abstract Truncated-
medicine, general & internal